

Orelabrutinib - Potential Best-in-Class BTK Inhibitor

- Orelabrutinib demonstrates compelling efficacy
 - In 80 patients with R/R CLL, at median follow-up of 32.3 months, ORR was 93.8%, CR was 24%, CRi was 2%. mDoR NR
 - In 99 patients with R/R MCL, at median follow-up of 23.8 months, ORR was 88%, CR was 37%, mDoR was 26-mo
- Orelabrutinib shows class leading safety and tolerability in patients with various b-cell malignancies
 - No case of ≥3 Grade 3 A-fib, rare case of major bleeding/severe hypertension/diarrhea
 - Most common AE are Grade 1-2, occurring during the early course of treatment
 - 5% of patients discontinued treatment due to AE, 2% were treatment related
- Orelabrutinib has demonstrated similar efficacy and safety profile in US patients
- Orelabrutinib has been granted Breakthrough Therapy Designation for r/r MCL indication by the FDA
- We are recruiting BTKi treatment naïve r/r MCL patients for our US registration study






Scan the QR code or visit TAVALISSEhcp.com to learn about a different approach to treatment.



© 2022 Rigel Pharmaceuticals, Inc. All rights reserved. TAVA_ITP-22I58 0822 TAVALISSE is a registered trademark of Rigel Pharmaceuticals, Inc.





A powerful way to fight cancer lives inside your body.

To fight cancer, we are developing immunotherapies that work with the body's natural defenses. Helping us get closer to a future where disease is a thing of the past. Learn more at www.janssen.com.

